Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Companies Business Strategies Leadership

Sanofi Accelerates Its ‘Carbon Neutral’ Pledge Ahead Of Climate Summit

Sets 2030 Carbon Neutrality Goal

  • News

Executive Summary

The France-headquartered company has brought forward its carbon neutral goal, making it one of the sector’s most proactive companies.

You may also be interested in...



AstraZeneca Looks To Take Sector Lead In Reducing Greenhouse Gas Emissions

Via a partnership with Vanguard Renewables, AstraZeneca is converting its US locations to renewable natural gas, part of a goal to achieve net zero for carbon emissions by 2045.

Dupixent Keeps Sanofi At Forefront Of European Pharma Growth

Sanofi is on a roll thanks to Dupixent and the blockbuster is providing breathing space even when some key pipeline assets are delayed.

Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy

The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.

Table

View full table

Topics

Tags:
Companies Business Strategies Leadership
Latest Headlines

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal

Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib

See All
UsernamePublicRestriction

Register

SC145320

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By